Early Access — free while we kick the tires
EdgarHawk

ALLEN HUBERT L

EXECUTIVE VICE PRESIDENT

Officer
2 filings analyzed · 1 company · Latest 2025-01-31

Companies

Company Buys Sells Direction
ABBOTT LABORATORIES ABT 0 8 Net selling

Activity

January 2025
2025-01-31 ABBOTT LABORATORIES ABT
high
Sell
189,788 shares
$24,342,304
Significance 6/10

EVP Allen Hubert sold 189,788 shares of ABT for $24,342,303.62 across 2 transactions, reducing holdings by 50.7%

ALLEN HUBERT L executed two separate sales totaling 189,788 shares (189.8K shares) for $24,342,303.62 ($24.3M) at a blended average price of $128.26, reducing his ABT holdings from 374,594 shares to 184,806 shares. His prior three sales at Abbott (all on 2024-10-21) demonstrated a 100% timing pattern at the 90-day mark, with negative returns following each sale. The stock currently trades at $127.93, near its 52-week high of $129.43 (-1.2%), while Abbott's fundamentals show annual revenue decline of -8.1% despite a substantial market cap of $221,888,855,399.09 ($221.9B) and P/E of 38.53. This substantial reduction in executive holdings—eliminating more than half of his position—occurs in a context of both strong near-term price momentum (+13.1% over 30 days) and concerning longer-term revenue headwinds at the company.

October 2024
2024-10-23 ABBOTT LABORATORIES ABT
high
Sell
157,421 shares
$18,424,298
Significance 6/10

EVP Allen Hubert sold 157,421 shares of ABT for $18.4M across 3 transactions at ~$117/share on 2024-10-21

On 2024-10-21, EVP Allen Hubert executed 3 separate sales totaling 157,421 shares for $18,424,298.42 at a blended average price of $117.04, reducing his holdings by 46.0% from 342,227 to 184,806 shares. The sale occurred near the upper end of ABT's 52-week range ($92.85–$120.96), with the stock currently at $117.01 and having gained 10.4% over the preceding 90 days. The substantive reduction in executive ownership—nearly half his stake divested in a single filing—deserves attention given the magnitude and concentration, though the absence of a disclosed trading plan or extraordinary circumstances limits what can be inferred about forward outlook. ABT's trailing P/E of 36.68 and annual revenue decline of 8.1% provide context for evaluating whether the sale reflects broader business headwinds or represents a routine liquidity event at market strength.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access